Search results for "dono"

showing 10 items of 572 documents

Catalytic hydrothermal liquefaction of municipal sludge assisted by formic acid for the production of next-generation fuels

2021

Abstract Hydrothermal liquefaction (HTL) of municipal sludge (MS) was studied at 325 °C and 30 min at 10 and 30% w/w concentration of MS using formic acid (FA) as a green liquid hydrogen donor both in the absence and in the presence of heterogeneous catalysts. Pellets of commercial NiMo/Al2O3, CoMo/Al2O3 and felt of activated carbon ACF 1600 were used as catalysts. The addition of FA at high MS loading allowed to increase the yields in BC from 41 to 62% and its H/C ratio from 1.80 to 2.01 leading to energy recovery (ER) higher than 100%.When heterogeneous catalysts were used together with FA, a marked improvement of BC yields and quality was obtained at 10% MS loading. This behavior was not…

Formic acidPelletsFormic acidHeterogeneous catalysisHeterogeneous catalystIndustrial and Manufacturing EngineeringCatalysischemistry.chemical_compoundmedicineElectrical and Electronic EngineeringHydrogen donorMunicipal sludgeCivil and Structural EngineeringFoulingChemistryMechanical EngineeringBuilding and ConstructionSettore ING-IND/27 - Chimica Industriale E TecnologicaBiorefineryPollutionBiorefineryHydrothermal liquefactionGeneral EnergyHydrothermal liquefactionActivated carbonmedicine.drugNuclear chemistryEnergy
researchProduct

Topological effects of a rigid chiral spacer on the electronic interactions in donor-acceptor ensembles

2005

Two triads (donor-spacer-acceptor), etTTF-BN-C 6 0 (6) and ZnP-BN-C 6 0 (7), in which electron donors (i.e., exTTF or ZnP) are covalently linked to C 6 0 through a chiral binaphthyl bridge (BN), have been prepared in a multistep synthetic procedure starting from a highly soluble enantiomerically pure binaphthyl building block (1). Unlike other oligomeric bridges, with hinaphthyl bridges, the conjugation between the donor and the acceptor units is broken and geometric conformational changes are facilitated. Consequently, distances and electronic interactions between the donor and C 6 0 are drastically changed. Both donor-spacer-acceptor (D-s-A) systems (i.e., 6 and 7) exhibit redox processes…

FullereneStereochemistryOrganic ChemistryTriad (anatomy)Donor-Acceptor EnsemblesGeneral ChemistrySettore CHIM/06 - Chimica OrganicaFluorescenceAcceptorRedoxCatalysischemistry.chemical_compoundmedicine.anatomical_structurePhotophysicschemistryFullereneCovalent bondUltrafast laser spectroscopymedicineTetrathiafulvalene
researchProduct

Study of the chemical reduction of the fumonisins toxicity using allyl, benzyl and phenyl isothiocyanate in model solution and in food products

2012

Abstract Fumonisins (FBs) are bioactive compounds produced by several strains of Fusarium spp. which contain a polyketide structure similar to sphinganine. These mycotoxins contain a free amino group that could work as an electron donor and react with the electrophile carbon present within the isothiocyanate (ITC) group. The objective of this study was to determine the effect of ITCs (allyl, benzyl and phenyl) on the stability of FB 1 , FB 2 and FB 3 . Firstly, PBS solutions at three pH levels (4, 7 and 9) were prepared and added with pairs of one FB (1 mg/L) plus one ITC (1 mg/L). Then, gaseous ITC was used to fumigate corn kernels and corn flour contaminated with FBs produced by Gibberell…

FusariumSpectrometry Mass Electrospray IonizationTime FactorsFood HandlingElectrospray ionizationFood ContaminationElectron donorToxicologyMass spectrometryTandem mass spectrometryFumonisinsZea maysPoisonschemistry.chemical_compoundDrug StabilityIsothiocyanatesTandem Mass SpectrometryMycotoxinChromatography High Pressure LiquidDecontaminationChromatographybiologyPhenyl isothiocyanateHydrogen-Ion Concentrationbiology.organism_classificationchemistryFumigationIsothiocyanateFood MicrobiologyToxicon
researchProduct

Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population

2013

Interpatient variability in drug response can be widely explained by genetically determined differences in metabolizing enzymes, drug transporters, and drug targets, leading to different pharmacokinetic and/or pharmacodynamic behaviors of drugs. Genetic variations affect or do not affect drug responses depending on their influence on protein activity and the relevance of such proteins in the pathway of the drug. Also, the frequency of such genetic variations differs among populations, so the clinical relevance of a specific variation is not the same in all of them. In this study, a panel of 33 single nucleotide polymorphisms in 14 different genes (ABCB1, ABCC2, ABCG2, CYP2B6, CYP2C19, CYP2C…

GenotypeCYP2B6Nod2 Signaling Adaptor ProteinOrganic Anion TransportersSingle-nucleotide polymorphismCYP2C19PharmacologyPolymorphism Single NucleotideWhite PeopleCytochrome P-450 Enzyme SystemGene FrequencyGenetic variationGenotypeHumansPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1GlucuronosyltransferaseAllele frequencyCYP2C9Methylenetetrahydrofolate Reductase (NADPH2)PharmacologyGeneticsbiologyMethyltransferasesMultidrug Resistance-Associated Protein 2Tissue DonorsTransplant RecipientsSpainInactivation MetabolicUDP-Glucuronosyltransferase 1A9biology.proteinSLCO1B1Immunosuppressive AgentsTherapeutic Drug Monitoring
researchProduct

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine mic…

2006

The LIS2T study was an open-label, multicenter study in which recipients of a primary liver transplant were randomized to cyclosporine microemulsion (CsA-ME) (Neoral) (n = 250) (monitoring of blood concentration at 2 hours postdose) C2 or tacrolimus (n = 245) (monitoring of trough drug blood level [predose]) C0 to compare efficacy and safety at 3 and 6 months and to evaluate patient status at 12 months. All patients received steroids with or without azathioprine. At 12 months, 85% of CsA-ME patients and 86% of tacrolimus patients survived with a functioning graft (P not significant). Efficacy was similar in deceased- and living-donor recipients. Significantly fewer hepatitis C–positive pati…

Graft RejectionMaleTime Factorsmedicine.medical_treatmentTACROLIMUSAzathioprineHepacivirusHEPATITIS-CLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compoundLiving DonorsLongitudinal StudiesC-2IMMUNOSUPPRESSIONHEPATITIS-C DIABETES-MELLITUS C-2 REPLICATION RECURRENCE SURVIVALGraft SurvivalHepatitis CTreatment Outcomesurgical procedures operativeCreatinineSURVIVALEmulsionsFemaleSteroidsImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyHepatitis C virusRenal functionRANDOMIZED STUDYAge DistributionInternal medicinemedicineDiabetes MellitusHumansHypoglycemic AgentsRECURRENCEMonitoring PhysiologicHepatitisTransplantationCreatinineHepatologybusiness.industryLIVER TRANSPLANTATIONDIABETES-MELLITUSmedicine.diseaseSurvival AnalysisTacrolimusSurgerychemistryREPLICATIONCYCLOSPORINESurgerybusinessFollow-Up Studies
researchProduct

Metabolomics discloses donor liver biomarkers associated with early allograft dysfunction

2014

Background & Aims Early allograft dysfunction (EAD) dramatically influences graft and patient outcome after orthotopic liver transplantation and its incidence is strongly determined by donor liver quality. Nevertheless, objective biomarkers, which can assess graft quality and anticipate organ function, are still lacking. This study aims to investigate whether there is a preoperative donor liver metabolomic biosignature associated with EAD. Methods A comprehensive metabolomic profiling of 124 donor liver biopsies collected before transplantation was performed by mass spectrometry coupled to liquid chromatography. Donor liver grafts were classified into two groups: showing EAD and immediate g…

Graft RejectionMalemedicine.medical_specialtyOrthotopic liver transplantationmedicine.drug_classBiopsyHistidine MetabolismGastroenterologyBile Acids and SaltsModel for End-Stage Liver DiseaseMetabolomicsPredictive Value of TestsRisk FactorsInternal medicineLipidomicsmedicineHumansMetabolomicsHistidinePhospholipidsHepatologyBile acidbusiness.industryMiddle AgedAllograftsTissue DonorsLiver TransplantationSphingomyelinsTransplantationLiverBiochemistryFemaleLysophospholipidsbusinessLiving donor liver transplantationBiomarkersJournal of Hepatology
researchProduct

Donor/recipient algorithm for management of the middle hepatic vein in right graft live donor liver transplantation

2010

Abstract Background The aim of this study was to delineate an algorithm for donor and recipient criteria and middle hepatic vein (MHV) management in right-graft live-donor liver transplantation (LDLT) on the basis of computerized 3-dimensional computed tomographic image analysis. Methods Data on 94 consecutive right-graft LDLTs were prospectively collected. Graft and remnant data for the first 23 cases were retrospectively evaluated by means of 3-dimensional computed tomographic reconstructions, and on the basis of that preliminary series, a graft selection algorithm using 3 parameters—hepatic vein dominance classification, graft and remnant graft volume/body weight ratios, and congestion v…

Graft RejectionMalemedicine.medical_specialtyTissue and Organ ProcurementLive donormedicine.medical_treatmentHepatic VeinsLiver transplantationliverBody weightRisk AssessmentPreoperative careComputed tomographicCohort StudiesImaging Three-DimensionalPostoperative ComplicationsPreoperative CareLiving DonorsmedicineGraft selectionHepatectomyHumansProspective StudiesAnalysis of VarianceSmall for size syndromebusiness.industryPatient SelectionGraft SurvivalGeneral MedicineLiver TransplantationSurgeryTreatment Outcomesurgical procedures operativeMathematikFemaleSurgeryHepatectomyTomography X-Ray ComputedbusinessAlgorithmAlgorithmsFollow-Up StudiesLiver CirculationThe American Journal of Surgery
researchProduct

High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System : success or waste of organs? The Eurotransplant 15-year all-centr…

2016

Item does not contain fulltext BACKGROUND: In the Eurotransplant Kidney Allocation System (ETKAS), transplant candidates can be considered for high-urgency (HU) status in case of life-threatening inability to undergo renal replacement therapy. Data on the outcomes of HU transplantation are sparse and the benefit is controversial. METHODS: We systematically analysed data from 898 ET HU kidney transplant recipients from 61 transplant centres between 1996 and 2010 and investigated the 5-year patient and graft outcomes and differences between relevant subgroups. RESULTS: Kidney recipients with an HU status were younger (median 43 versus 55 years) and spent less time on the waiting list compared…

Graft RejectionMalemedicine.medical_treatmentMedizin030232 urology & nephrologygraft survival030230 surgery0302 clinical medicineSurveys and QuestionnairesDIALYSISYoung adultChildKidney transplantationCANDIDATESKidneyMiddle AgedPrognosis3. Good healthEuropeMulticenter Studymedicine.anatomical_structureNephrologyChild PreschoolFemaleHemodialysisAdultReoperationmedicine.medical_specialtykidneyTissue and Organ ProcurementAdolescentWaiting ListsDonor SelectionResource AllocationYoung Adult03 medical and health sciencespatient survivalInternal medicinemedicineJournal ArticleHumansComparative StudyRenal replacement therapyDialysisAgedbusiness.industryDonor selectionInfant NewbornInfantmedicine.diseaseKidney TransplantationSurgeryTransplantationhigh-urgencyPRIORITYSURVIVAL BENEFITrenalHuman medicineRenal disorders Radboud Institute for Health Sciences [Radboudumc 11]businessWAITING TIMEtransplantationNephrology, dialysis, transplantation
researchProduct

Preclinical report on allogeneic uterus transplantation in non-human primates

2013

Study question Is it possible to perform allogeneic uterus transplantation (UTx) with a donation from a live donor in a non-human primate species and what immunosuppression is needed to prevent rejection? Summary answer Allogeneic UTx in the baboon is a donor- and recipient-safe surgical procedure; immunosuppression with induction therapy and a triple protocol should be used. What is known already UTx may become a treatment for absolute uterine factor infertility. Autologous UTx models have been developed in non-human primates with reports on long-term survival of the uterine grafts. STUDY DESIGN, SIZEAND DURATION: This experimental study included 18 female baboons as uterus donors and 18 f…

Graft Rejectionmedicine.medical_specialtymedicine.medical_treatmentUterusTacrolimusMaintenance ChemotherapyAdrenal Cortex Hormonesmedicine.arteryUterus transplantationmedicineLiving DonorsAnimalsTransplantation HomologousExternal iliac veinAntilymphocyte SerumImmunosuppression TherapyUterine DiseasesHysterectomybusiness.industryRehabilitationGraft SurvivalUterusObstetrics and GynecologyImmunosuppressionInduction ChemotherapyMycophenolic AcidInternal iliac arteryTacrolimusSurgeryTransplantationDisease Models Animalmedicine.anatomical_structureReproductive MedicineFeasibility StudiesDrug Therapy CombinationFemalebusinessInfertility FemalePapio
researchProduct

Typing of KIR genes in unrelated hematopoietic stem cell transplants: influence of the donor KIR genotype on the outcome of the transplant.

In recent years, the anti-leukemic potential of Natural Killer (NK) cells and their role in hematologic malignancies and in Hematopoietic Stem Cell Transplants (HSCT) has attracted greater interest and a recent study by Cooley S. et al. showed a better clinical outcome when patients with Acute Myeloid Leukemia received a transplant from unrelated Group B KIR haplotypes donors. As a consequence of these results, an algorithm called "KIR B-content score" was formulated, based on the number of centromeric and telomeric Group B KIR haplotypes gene-content motifs. The KIR B-content score defines three categories of donors: Neutral donors have none or one KIR B motifs, Better donors have two or m…

GvL effectUDHSCT; NK Cells; Donor KIR B Status; AML; GvL effect; [Keywords]AMLKeywords: UDHSCTNK CellDonor KIR B Statu
researchProduct